However, it should be cautioned that milli-molar doses of short-chain fatty acids are required for HDAC inhibition and, thus, these compounds likely elicit off-target actions that may contraindicate their therapeutic use for treating CVD/HF. The gene discussed is HDAC9; the disease is hydrops fetalis.